Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes”
Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, dependi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1984 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: World journal of urology - 1983, 2(1984) vom: Jan., Seite 59-63 |
| Übergeordnetes Werk: |
volume:2 ; year:1984 ; month:01 ; pages:59-63 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ203315065 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ203315065 | ||
| 003 | DE-627 | ||
| 005 | 20230506102335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1984 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ203315065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| 264 | 1 | |c 1984 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Raghavan, Derek |4 oth | |
| 773 | 0 | 8 | |i in |t World journal of urology |d 1983 |g 2(1984) vom: Jan., Seite 59-63 |w (DE-627)NLEJ188992332 |w (DE-600)1463303-6 |x 1433-8726 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:1984 |g month:01 |g pages:59-63 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00326936 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 1984 |c 1 |h 59-63 |g 5 | ||
| matchkey_str |
article:14338726:1984----::xetnteayociiasaenneioaosemelacr |
|---|---|
| hierarchy_sort_str |
1984 |
| publishDate |
1984 |
| allfields |
(DE-627)NLEJ203315065 DE-627 ger DE-627 rakwb eng Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” 1984 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. Springer Online Journal Archives 1860-2002 Raghavan, Derek oth in World journal of urology 1983 2(1984) vom: Jan., Seite 59-63 (DE-627)NLEJ188992332 (DE-600)1463303-6 1433-8726 nnns volume:2 year:1984 month:01 pages:59-63 extent:5 http://dx.doi.org/10.1007/BF00326936 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 2 1984 1 59-63 5 |
| spelling |
(DE-627)NLEJ203315065 DE-627 ger DE-627 rakwb eng Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” 1984 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. Springer Online Journal Archives 1860-2002 Raghavan, Derek oth in World journal of urology 1983 2(1984) vom: Jan., Seite 59-63 (DE-627)NLEJ188992332 (DE-600)1463303-6 1433-8726 nnns volume:2 year:1984 month:01 pages:59-63 extent:5 http://dx.doi.org/10.1007/BF00326936 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 2 1984 1 59-63 5 |
| allfields_unstemmed |
(DE-627)NLEJ203315065 DE-627 ger DE-627 rakwb eng Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” 1984 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. Springer Online Journal Archives 1860-2002 Raghavan, Derek oth in World journal of urology 1983 2(1984) vom: Jan., Seite 59-63 (DE-627)NLEJ188992332 (DE-600)1463303-6 1433-8726 nnns volume:2 year:1984 month:01 pages:59-63 extent:5 http://dx.doi.org/10.1007/BF00326936 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 2 1984 1 59-63 5 |
| allfieldsGer |
(DE-627)NLEJ203315065 DE-627 ger DE-627 rakwb eng Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” 1984 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. Springer Online Journal Archives 1860-2002 Raghavan, Derek oth in World journal of urology 1983 2(1984) vom: Jan., Seite 59-63 (DE-627)NLEJ188992332 (DE-600)1463303-6 1433-8726 nnns volume:2 year:1984 month:01 pages:59-63 extent:5 http://dx.doi.org/10.1007/BF00326936 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 2 1984 1 59-63 5 |
| allfieldsSound |
(DE-627)NLEJ203315065 DE-627 ger DE-627 rakwb eng Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” 1984 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. Springer Online Journal Archives 1860-2002 Raghavan, Derek oth in World journal of urology 1983 2(1984) vom: Jan., Seite 59-63 (DE-627)NLEJ188992332 (DE-600)1463303-6 1433-8726 nnns volume:2 year:1984 month:01 pages:59-63 extent:5 http://dx.doi.org/10.1007/BF00326936 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 2 1984 1 59-63 5 |
| language |
English |
| source |
in World journal of urology 2(1984) vom: Jan., Seite 59-63 volume:2 year:1984 month:01 pages:59-63 extent:5 |
| sourceStr |
in World journal of urology 2(1984) vom: Jan., Seite 59-63 volume:2 year:1984 month:01 pages:59-63 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
World journal of urology |
| authorswithroles_txt_mv |
Raghavan, Derek @@oth@@ |
| publishDateDaySort_date |
1984-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188992332 |
| id |
NLEJ203315065 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ203315065</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506102335.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1984 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ203315065</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes”</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1984</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raghavan, Derek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">World journal of urology</subfield><subfield code="d">1983</subfield><subfield code="g">2(1984) vom: Jan., Seite 59-63</subfield><subfield code="w">(DE-627)NLEJ188992332</subfield><subfield code="w">(DE-600)1463303-6</subfield><subfield code="x">1433-8726</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1984</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:59-63</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00326936</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1984</subfield><subfield code="c">1</subfield><subfield code="h">59-63</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188992332 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1433-8726 |
| topic_title |
Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d r dr |
| hierarchy_parent_title |
World journal of urology |
| hierarchy_parent_id |
NLEJ188992332 |
| hierarchy_top_title |
World journal of urology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188992332 (DE-600)1463303-6 |
| title |
Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| spellingShingle |
Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| ctrlnum |
(DE-627)NLEJ203315065 |
| title_full |
Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| journal |
World journal of urology |
| journalStr |
World journal of urology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1984 |
| contenttype_str_mv |
zzz |
| container_start_page |
59 |
| container_volume |
2 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
expectant therapy for clinical stage a nonseminomatous germ-cell cancers of the testis? a qualified “yes” |
| title_auth |
Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| abstract |
Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. |
| abstractGer |
Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. |
| abstract_unstemmed |
Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes” |
| url |
http://dx.doi.org/10.1007/BF00326936 |
| remote_bool |
true |
| author2 |
Raghavan, Derek |
| author2Str |
Raghavan, Derek |
| ppnlink |
NLEJ188992332 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| up_date |
2024-07-06T10:21:41.853Z |
| _version_ |
1803824714851811328 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ203315065</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506102335.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1984 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ203315065</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Expectant therapy for clinical stage A nonseminomatous germ-cell cancers of the testis? A qualified “Yes”</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1984</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Most patients with testicular cancer can ultimately be cured. In early-stage disease, retroperitoneal lymph node dissection or radiotherapy can cure more than 90% of patients, and chemotherapy is associated with long-term remission in 60% to more than 90% of patients with metastases, depending on the extent of disease. Because of the high salvage rate with chemotherapy, efforts are now being directed toward reducing the toxicity of primary management. In several centers, a “surveillance” policy for selected patients with clinical Stage A nonseminomatous germ-cell tumors appears to be safe: 80% of these patients may be cured by orchiectomy alone, thus avoiding the adverse effects of lymph node dissection or radiotherapy; the remaining 20% will require chemotherapy. This approach should be used only in referral centers with a specialty interest in testicular cancer and excellent facilities for monitoring and followup.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raghavan, Derek</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">World journal of urology</subfield><subfield code="d">1983</subfield><subfield code="g">2(1984) vom: Jan., Seite 59-63</subfield><subfield code="w">(DE-627)NLEJ188992332</subfield><subfield code="w">(DE-600)1463303-6</subfield><subfield code="x">1433-8726</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:1984</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:59-63</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00326936</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">1984</subfield><subfield code="c">1</subfield><subfield code="h">59-63</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.3997135 |